The startup develops targeted therapeutics for sarcopenia and various cancers, focusing on conditions such as Duchenne muscular dystrophy, ALS, and genomically defined rare cancers. By utilizing specific drug formulations, the company aims to enhance treatment efficacy in the healthcare and pharmaceutical sectors.
Funding
Funding not disclosed
Founders
Product
Problem
Many diseases, including sarcopenia, muscular dystrophy, and certain cancers, lack effective long-term treatments due to rapid drug clearance and the need for frequent dosing, which can lead to poor patient compliance and suboptimal therapeutic outcomes. Current therapeutic options often fail to maintain consistent drug concentrations in the body, resulting in fluctuating efficacy and increased side effects.
Solution
ImmunoForge is a biopharmaceutical company developing targeted therapeutics using its proprietary ELP (Elastin-like Polypeptide) platform technology to extend drug half-life and enhance treatment efficacy. The ELP platform enables the creation of long-acting drug formulations that reduce dosing frequency, maintain stable drug concentrations, and improve patient adherence. ImmunoForge's pipeline includes novel therapies for sarcopenia, Duchenne muscular dystrophy, chronic myeloid leukemia, and genomically defined rare cancers, with several candidates in preclinical and clinical development. By leveraging the ELP platform, ImmunoForge aims to provide more convenient and effective treatment options for patients with debilitating diseases.
Target Audience
The primary target audience includes patients suffering from sarcopenia, muscular dystrophy, chronic myeloid leukemia, polymyositis, dermatomyositis, and other rare cancers, as well as pharmaceutical companies seeking to license or co-develop novel long-acting therapeutics.
Features
- ELP (Elastin-like Polypeptide) platform technology for half-life extension of therapeutic molecules
- Pipeline of long-acting therapeutics targeting sarcopenia, Duchenne muscular dystrophy, and various cancers
- Froniglutide: A drug in Phase 2 clinical trials for the treatment of polymyositis and dermatomyositis
- Pemziviptadil: A drug in Phase 2 clinical trials for the treatment of Duchenne Muscular Dystrophy Cardiomyopathy
- KF1601: A drug in Phase 1 clinical trials for the treatment of chronic myelogenous leukemia
- PF1805, PF1806, PF1807, PF1802, PF1803: Preclinical assets
- Ability to create fusion proteins with tunable half-lives
- Improved pharmacokinetic profiles for enhanced drug efficacy and reduced dosing frequency